Breaking News

WuXi Advanced Therapies Launches AAV Vector Suspension Platform

Enables cell and gene therapies to be developed, manufactured, and released faster and with greater predictability globally.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

WuXi Advanced Therapies, a global contract development and manufacturing organization (CDMO) offering end-to-end contract services for the advance therapies industry, has expanded its service capabilities by offering a fully integrated adeno-associated virus (AAV) Vector Suspension Platform to help accelerate the timeline for cell and gene therapy development, manufacturing and release while providing greater predictability.   This service will provide advanced therapy companies worldwide with a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters